Hit confirmation of pemigatinib was further assessed in an expanded 10 × 10 drug combination matrix with AMG 510 across KRAS G12C-mutant lung cancer cell lines, including the previously identified mesenchymal-like cell line LU99 [18]. Here, KRAS is linked to lung carcinoma.